Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $202,224.80 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.60, for a total value of $202,224.80. Following the completion of the transaction, the insider owned 540,132 shares in the company, valued at $12,206,983.20. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.92, for a total value of $311,366.64.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total value of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total value of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.96, for a total value of $314,400.00.

Kestra Medical Technologies Trading Down 3.4%

Shares of Kestra Medical Technologies stock opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00. The company’s fifty day simple moving average is $22.78 and its 200-day simple moving average is $22.52. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -10.36 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on KMTS. The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, BTIG Research upped their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus price target of $27.83.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of hedge funds have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in Kestra Medical Technologies in the first quarter valued at about $11,036,000. Woodline Partners LP acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth approximately $2,510,000. Jane Street Group LLC bought a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $756,000. Geode Capital Management LLC raised its stake in shares of Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after acquiring an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Kestra Medical Technologies in the 2nd quarter worth approximately $256,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.